Literature DB >> 19321476

Rituximab for treatment of ocular inflammatory disease: a series of four cases.

P A Kurz1, E B Suhler, D Choi, J T Rosenbaum.   

Abstract

Rituximab may be effective in the treatment of ocular inflammatory disease. Dosing is less frequent than many medications currently available. Four cases are reported, each of which appeared to have responded well to treatment with rituximab, although patient 2 was able to remain on a low dose of prednisone for only 2 months. The ongoing pilot study will hopefully provide additional insight into the benefit of rituximab for treatment of scleritis and idiopathic orbital inflammatory disease.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19321476     DOI： 10.1136/bjo.2007.133173

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


  11 in total

Review 1.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

Review 2.  Biologic therapy for refractory scleritis: a new treatment perspective.

Authors:  Tania Sales de Alencar de Fidelix; Luis Antonio Vieira; Denise de Freitas; Virginia Fernandes Moça Trevisani
Journal:  Int Ophthalmol       Date:  2015-08-29       Impact factor: 2.031

3.  Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.

Authors:  Eric B Suhler; Lyndell L Lim; Robert M Beardsley; Tracy R Giles; Sirichai Pasadhika; Shelly T Lee; Alexandre de Saint Sardos; Nicholas J Butler; Justine R Smith; James T Rosenbaum
Journal:  JAMA Ophthalmol       Date:  2014-05       Impact factor: 7.389

4.  Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial.

Authors:  Jared E Knickelbein; William R Tucker; Nirali Bhatt; Karen Armbrust; David Valent; Dominic Obiyor; Robert B Nussenblatt; H Nida Sen
Journal:  Am J Ophthalmol       Date:  2016-09-20       Impact factor: 5.258

Review 5.  An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma.

Authors:  Faruque Ghanchi; Rupert Bourne; Susan M Downes; Richard Gale; Christina Rennie; Ian Tapply; Sobha Sivaprasad
Journal:  Eye (Lond)       Date:  2022-01-01       Impact factor: 4.456

Review 6.  Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.

Authors:  Sirichai Pasadhika; James T Rosenbaum
Journal:  Biologics       Date:  2014-02-15

Review 7.  Autoimmune and autoinflammatory mechanisms in uveitis.

Authors:  Richard W Lee; Lindsay B Nicholson; H Nida Sen; Chi-Chao Chan; Lai Wei; Robert B Nussenblatt; Andrew D Dick
Journal:  Semin Immunopathol       Date:  2014-05-24       Impact factor: 9.623

8.  Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS)-report 4: analysis and outcome of scleritis in an East Asian population.

Authors:  Muhammad Amir Bin Ismail; Rachel Hui Fen Lim; Helen Mi Fang; Elizabeth Poh Ying Wong; Ho Su Ling; Wee Kiak Lim; Stephen C Teoh; Rupesh Agrawal
Journal:  J Ophthalmic Inflamm Infect       Date:  2017-02-15

9.  Commentary: Rituximab in scleritis.

Authors:  Parthopratim Dutta Majumder
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

10.  Successful corticosteroid-sparing effect of rituximab in the treatment of refractory idiopathic orbital inflammatory disease.

Authors:  Emily H Shao; Andreas Karydis; Maria Gemenetzi; Simon R J Taylor
Journal:  Case Rep Ophthalmol       Date:  2013-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.